2 not yet recruiting, 1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Yongjun Chen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Volume-Restricted Resection for Perihilar Cholangiocarcinoma Cholangiocarcinoma, Hilar | Not yet recruiting | Yongjun Chen | 300 | 2026-01-01 | 2025-09-02 | |
| Impact of Vascular Resection on Survival and Postoperative Outcomes in Patients With Hilar Cholangiocarcinoma: A Retrospective Study No Intervention: Observational Cohort - Cholangiocarcinoma, Hilar | Not yet recruiting | Yongjun Chen | 300 | 2025-12-01 | 2025-12-31 | |
| A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer Adebrelimab combined with the GC regimen and Apatinib - Biliary Tract Cancer, Biliary Tract Cancer (CCA) | Phase 2 | Recruiting | Yongjun Chen | 37 | 2025-08-14 | 2025-08-22 |
Klatskin Tumor (2) · Biliary Tract Neoplasms (1)
apatinib (1)
China (1)